It is a subject, of course, that resonates in the United States and particularly in California, where the $3 billion state stem cell agency is running out of cash and needs a boost.
The article appeared on Labiotech, which bills itself as "leading digital media covering the European biotech industry." Written by Helen Albert, the piece actually lists more than a trio of "teething problems" for the stem cell industry. They are:
- "A reliable, consistent and scalable manufacturing system"
- "Excessively high pricing"
- Safety, regulation and a knowledgeable workforce
Alan O’Connell, partner at Irish life sciences VC Seroba
2019 certainly appears to be the start, if not the end, of cell therapy’s move to the big time."